LAB
Standard BioTools Inc. (LAB) Economic Moat Analysis (2026)
Overall Score
Profitability Returns
Returns remain deeply negative, with ROIC at -8.3%, ROE at -18.2%, and ROA at -13.9%.
Operating margins are still severely negative, with EBIT margin at -116.9% and operating margin at -94.8%.
Gross margin is positive at 49.1%, but it is not translating into bottom-line profitability.
Balance Sheet Financial Resilience
Liquidity remains very strong, with a current ratio of 9.1x and quick ratio of 8.8x.
Debt appears modest relative to market value, with debt-to-equity at 0.05x and debt-to-assets at 4.5%.
Net debt to EBITDA remains elevated because EBITDA is negative, limiting the usefulness of leverage ratios.
Cash Generation Capital Efficiency
Cash generation is still negative, with operating cash flow at -$0.95 per revenue dollar and free cash flow at -$0.30 FCF yield.
Capital efficiency remains poor, with asset turnover at 0.13x and working capital turnover at 0.18x.
The business is not converting earnings into cash, as income quality is deeply negative.
Competitive Positioning
The company retains some pricing support at the gross margin level, but the moat is not evident in sustained operating profitability.
Low price-to-book and price-to-sales multiples suggest the market is not assigning a strong franchise premium.
No recent news indicates a new strategic advantage, product win, or structural improvement.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Standard BioTools Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

